Dear Mr. Ulatowski:

Please refer to your supplemental new drug application (sNDA) dated November 13, 2019, received November 13, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lynparza® (olaparib) tablets, 100 mg and 150 mg.

This Prior Approval supplemental new drug application proposes a new indication for the use of Lynparza® (olaparib) in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:

- a deleterious or suspected deleterious BRCA mutation, and/or
- genomic instability.

Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using...
the FDA automated drug registration and listing system (eLIST), as described at
FDA.gov.\textsuperscript{1} Content of labeling must be identical to the enclosed labeling (text for the
Prescribing Information and Medication Guide), with the addition of any labeling
changes in pending “Changes Being Effected” (CBE) supplements, as well as annual
reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for
industry \textit{SPL Standard for Content of Labeling Technical Qs and As.}\textsuperscript{2}

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling
changes for this NDA, including CBE supplements for which FDA has not yet issued an
action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word
format, that includes the changes approved in this supplemental application, as well as
annual reportable changes. To facilitate review of your submission(s), provide a
highlighted or marked-up copy that shows all changes, as well as a clean Microsoft
Word version. The marked-up copy should provide appropriate annotations, including
supplement number(s) and annual report date(s).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for
new active ingredients (which includes new salts and new fixed combinations), new
indications, new dosage forms, new dosing regimens, or new routes of administration
are required to contain an assessment of the safety and effectiveness of the product for
the claimed indication in pediatric patients unless this requirement is waived, deferred,
or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are
exempt from this requirement.

**FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)**

We remind you of your postmarketing commitments:

3525-2 Submit the final report of progression-free survival (PFS) with analyses
and datasets from patients with tumour BRCA-mutated advanced
epithelial ovarian, fallopian tube, and primary peritoneal cancer on the
ongoing clinical trial entitled, “A Randomized, Double-Blind, Phase III Trial
of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV

\textsuperscript{1} http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
\textsuperscript{2} We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance (PAOLA-1)."

We have reviewed your submission and conclude that the above commitment (3525-2) was fulfilled.

We remind you that there is a postmarketing commitment listed in the December 19, 2018, approval letter that is still open.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitment:

3819-1 Submit the final overall survival analysis and datasets with the final report from the Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First Line Treatment, (PAOLA-1), that may inform product labeling.

The timetable you submitted on April 10, 2020, states that you will conduct this study according to the following schedule:

- **Final Protocol Submission:** 11/2019 (completed)
- **Trial Completion:** 03/2022
- **Final Report Submission:** 09/2022

Submit clinical protocols to your IND 075918 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “Postmarketing Commitment Protocol,” “Postmarketing Commitment Final Report,” or “Postmarketing Commitment Correspondence.”

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)
final guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs. 3

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov. 4 Information and Instructions for completing the form can be found at FDA.gov. 5

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Kelly Mach, Regulatory Project Manager, at Duyen.Mach@fda.hhs.gov or 301-796-5822.

Sincerely,

{See appended electronic signature page}

Laleh Amiri-Kordestani, MD
Supervisory Associate Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):
- Content of Labeling
  - Prescribing Information
  - Medication Guide

---

3 For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 4605349
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DUYEN M MACH  
05/08/2020 09:26:29 AM

LALEH AMIRI KORDESTANI  
05/08/2020 09:37:35 AM